Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial

Chow, Edward; Linden, Yvette M. van der; Roos, Daniel; Hartsell, William F.; Hoskin, Peter; Wu, Jackson; Brundage, Michael; Nabid, Abdenour; Tissing-Tan, C.; Oei, Bing; Babington, Scott; Demas, William F.; Wilson, C. W.; Meyer, Ralph M.; Chen, Bingshu E.; Wong, Rebecca

doi:10.1016/s1470-2045(13)70556-4

Cited by 245 publications

(146 citation statements)

References 17 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…Traditionally, local therapy such as RT is generally reserved for symptomatic palliation (21,22). SBRT enables precise delivery of ablative radiation to the target, with minimum dose to the surrounding normal tissue, using image guidance and immobilization devices (23).…”

Section: Discussionmentioning

confidence: 99%

Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report

et al. 2015

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report

et al. 2015

View full text Add to dashboard Cite

“…The details of the study have been reported before [11,12]. Patients completed the BPI [2] and/or the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) [13] at baseline.…”

Section: Methodsmentioning

confidence: 99%

Revisiting classification of pain from bone metastases as mild, moderate, or severe based on correlation with function and quality of life

Chow

Ding

Parulekar

et al. 2015

Support Care Cancer

Self Cite

View full text Add to dashboard Cite

Purpose The objective of our study was to determine the optimal cut points for classification of pain scores as mild, moderate, and severe based on interference with function and quality of life (QOL). Methods We evaluated 822 patients who completed the Brief Pain Inventory (BPI) and/or the European Organization for Research and Treatment of Cancer (EORTC) QOL Questionnaire Core 30 (QLQ-C30) prior to receiving repeat radiation therapy for previously irradiated painful bone metastases. Optimal cut points for mild, moderate, and severe pain were determined by the MANOVA that yielded the largest F ratio for the between category effect on the seven interference items of BPI and the six functional domains of QOL (physical, role, emotional, cognitive, social functioning, and global QOL) as indicated by Pillai's Trace, Wilk's λ, and Hostelling's Trace F statistics. Results For BPI and for QOL domains separately, the two largest F ratios for Wilk's λ, Pillai's Trace, and Hotelling's Trace F statistics were from the cut points 4, 8 and 6, 8. When combining both, the optimal cut points were 4, 8 with 1-4 (mild), 5-8 (moderate), and 9-10 (severe). With this classification, the mean scores of all the seven interference items in BPI and the six functional domains were all highly statistically Electronic supplementary material The online version of this article

show abstract

“…Reirradiation might be an option to palliate pain in patients who have had no pain relief after previously receiving radiation therapy, as well as in those who have had partial improvement in pain and who might receive additional benefit from repeat treatment, or in those whose pain has recurred after an initial satisfactory response [4]. The evidence for the safety and efficacy of reirradiation to previously irradiated areas of peripheral bone metastases for pain was derived from both prospective studies and retrospective data [2,[5][6][7]. In the systematic review by Wong et al, the complete response and partial response rates after reirradiation were 20% and 50%, respectively, and the overall pain response rate was 68% [7].…”

Section: Introductionmentioning

confidence: 99%

Palliative Reirradiation for Painful Bone Metastases: Clinical Cases and Literature Review

et al. 2017

View full text Add to dashboard Cite

Summary:Reirradiation to previously irradiated peripheral bone metastases for pain has been shown to be safe and effective, but no specific trial has been completed to define the indications for reirradiation of patients with recurrent symptoms of metastatic bone disease. Thus, we aimed to assess the effectiveness and prognostic factors of reirradiation for painful bone metastases. To do so, we reviewed the cases of 14 patients with painful bone metastases who had undergone reirradiation at our hospital. A favorable pain response after reirradiation was achieved in 50% (7/14) of the patients. An interval from initial radiotherapy > 6 months was a significant prognostic factor for pain response (p = 0.03). Performance status was correlated with pain response, with borderline significance (p = 0.06). No severe adverse events were reported. We conclude that reirradiation of painful bone metastases is effective in providing pain relief, especially for patients with a long interval from initial radiation and good performance status.

show abstract

Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial

Cited by 245 publications

References 17 publications

Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report

Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report

Revisiting classification of pain from bone metastases as mild, moderate, or severe based on correlation with function and quality of life

Palliative Reirradiation for Painful Bone Metastases: Clinical Cases and Literature Review

Contact Info

Product

Resources

About